All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Talquetamab is a G protein-coupled receptor family C class 5 member D (GPRC5D) targeting bispecific antibody which was granted accelerated approval by the U.S. Food and Drug Administration and conditional marketing authorization by the European Commission. In both approvals, patients must have been treated with a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody; making talquetamab the first GPRC5D-targeted bispecific antibody to be approved for use in relapsed/refractory multiple myeloma (RRMM).
Here, we summarize a retrospective study published by Lery et al.1 in Journal of the American Academy of Dermatology on the dermatological toxicities associated with the use of talquetamab for the treatment of RRMM.
Figure 1. Dermatological toxicities*
*Data from Lery, et al.1
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox